Biomedical subjects

B D'Acremont

Publications and source records attributed to B D'Acremont.

3 recordsLinked to original sources

PubMed1991

[Mediastinal exploration for hyperparathyroidism].

Five per cent of parathyroid adenomas are situated in the mediastinum. Many of them are accessible via a cervical incision: virtually all posterior mediastinal adenomas, by dissecting well behind the oesophagus, and most intrathymic adenomas, by cervical exteriorisation of the thymus. Finally, the indications for sternotomy are are: less than 2% of operations for hyperparathyroidism. After describing the technical details, the authors review the indications, the imaging modalities used and the results of their last 20 sternotomies.

Adenoma↗

PubMed1991

[Tracheal injury caused by intubation for compressive endothoracic goiter].

The tube cannot pass along the marked curve of the trachea, which is displaced by a large goiter extending into the posterior mediastinum. The trachea is perforated in a low thoracic location. Tracheal suture and exeresis of the goiter are performed through sternotomia. This serious accident seems to be exceptional. Can it be predicted?

Aged↗

PubMed1990

[Chemotherapy in cancer of the prostate].

The most classical treatment of metastatic prostatic adenocarcinoma is hormone therapy. Most often, chemotherapy is proposed only when the tumor becomes hormonally unresponsive. But evaluation of its efficacy is impaired by the diversity of inclusion criteria used and by the different criteria of response assessment. Results of randomized, comparative studies show that all cytotoxic agents currently available have a similar response rate (about 30 to 40%). Use of combined chemotherapy does not seem to significantly improve these results. Several others ways have been proposed which attempt to improve the efficacy of chemotherapy (androgen stimulation, priming chemotherapy, adjuvant or neo-adjuvant chemotherapy...) but, most probably, progress will come from the discovery of more effective and selective cytotoxic agents, and not from the increase of clinical trials with the same agents.

Antineoplastic Agents↗